Sphingosine pathway as a possible druggable target for pain management

16 July 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Sphingolipids bear a spingoid base, and a fatty amino alcohol known as sphingosine. Sphingosine in converted to sphingosine phosphate (S1P) catalyzed by sphingosine kinase enzymes. S1P is transported across the plasma membrane and binds to extracellular S1P receptors. S1P is found in high concentration in plasma of patients with rheumatoid arthritis and at inflammation sites. Targeting S1P receptors might be a suitable strategy for discovery of drugs for treatment of neuropathic pain.

Keywords

Sphingosine
ceramide
neuropathic pain
diabetic neuropathy
drug discovery

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.